Gallego J, Jiménez Cruz J F, Gobernado M, Llopis B, Vidal J, Server G, Ruiz J L, David Vera C
Arch Esp Urol. 1989 Mar;42(2):116-9.
We performed a comparative study between the monobactam antibiotic aztreonam and the aminoglycoside tobramycin in patients diagnosed as having acute pyelonephritis. The respective doses were 1 gr. IM daily for 7 days, and 100 mgr. IM q 12 h for the same period of time. Clinically, 100% of uncomplicated acute pyelonephritis and 87.5% of complicated infections cured with aztreonam. Tobramycin achieved an 80% cure rate for both types of infections. Microbiologically aztreonam was effective in all uncomplicated acute pyelonephritis, and in 69.56% of the complicated cases (overall microbiological cure rate = 78.7%). The therapeutic failures were ascribable to infections from S. faecalis, an organism naturally resistant to aztreonam. Thus, the microbiological cure rate was 84.2% in complicated pyelonephritis from organisms sensitive to this antimicrobial. The microbiological cure rate for tobramycin was 70% in acute uncomplicated, and 80% in complicated infections. We observed a good clinical and biological tolerance to both antimicrobials. No side effects were observed. Serum and blood biochemical analyses, and coagulation tests revealed no changes.
我们对被诊断为急性肾盂肾炎的患者进行了单环β-内酰胺类抗生素氨曲南和氨基糖苷类抗生素妥布霉素的对比研究。各自的剂量为每天1克，肌内注射，共7天，以及每12小时100毫克，肌内注射，疗程相同。临床上，100%的非复杂性急性肾盂肾炎和87.5%的复杂性感染用氨曲南治愈。妥布霉素对两种类型感染的治愈率为80%。在微生物学方面，氨曲南对所有非复杂性急性肾盂肾炎有效，对69.56%的复杂性病例有效（总体微生物学治愈率 = 78.7%）。治疗失败归因于粪肠球菌感染，该菌对氨曲南天然耐药。因此，对于对这种抗菌药物敏感的微生物引起的复杂性肾盂肾炎，微生物学治愈率为84.2%。妥布霉素在急性非复杂性感染中的微生物学治愈率为70%，在复杂性感染中为80%。我们观察到两种抗菌药物在临床和生物学上都有良好的耐受性。未观察到副作用。血清和血液生化分析以及凝血试验均未显示有变化。
